Search results
Results from the WOW.Com Content Network
Lamivudine has been used for treatment of chronic hepatitis B at a lower dose than for treatment of HIV/AIDS. It improves the seroconversion of e-antigen positive hepatitis B and also improves histology staging of the liver. Long-term use of lamivudine leads to emergence of a resistant hepatitis B virus (YMDD) mutant. [11]
Viral hepatitis is liver inflammation due to a viral infection. [1] [2] It may present in acute form as a recent infection with relatively rapid onset, or in chronic form, typically progressing from a long-lasting asymptomatic condition up to a decompensated hepatic disease and hepatocellular carcinoma (HCC). [3]
Hepatitis A and E are mainly spread by contaminated food and water. [3] Hepatitis B is mainly sexually transmitted, but may also be passed from mother to baby during pregnancy or childbirth and spread through infected blood. [3] Hepatitis C is commonly spread through infected blood such as may occur during needle sharing by intravenous drug ...
For example, for the treatment of genotypes 1, 4, 5, and 6 hepatitis C infections, sofosbuvir can be used in combination with the viral NS5A inhibitor ledipasvir. [16] In genotype 2 and 3 HCV infections, sofosbuvir can be used in combination with daclatasvir. For the treatment of cases with cirrhosis or liver transplant patients, weight-based ...
Zieve's syndrome is an acute metabolic condition that can occur during withdrawal from prolonged heavy alcohol use. It is defined by hemolytic anemia (with spur cells and acanthocytes), hyperlipoproteinemia (excessive blood lipoprotein), jaundice (elevation of unconjugated bilirubin), and abdominal pain. [1]
The Federal Reserve announced another cut to its benchmark interest rates yesterday, dropping the Fed rate by 25 basis points to a range of 4.25% to 4.50% — the third consecutive time it's ...
From January 2008 to May 2011, if you bought shares in companies when Donald H. Schmude joined the board, and sold them when he left, you would have a -47.9 percent return on your investment, compared to a -8.2 percent return from the S&P 500.
Without treatment, the ten-year survival rate for individuals with symptomatic autoimmune hepatitis is 50%. However, with treatment, the ten-year survival rate is above 90%. Despite the benefits of treatment, people with autoimmune hepatitis generally have a lower transplant-free survival than the general population.